Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma. (September 2013)

• Record Type: Journal Article
• Authors: Moscato, Tiziana; Fedele, Roberta; Messina, Giuseppe; Irrera, Giuseppe; Console, Giuseppe; Martino, Massimo
• Is Part Of: Expert opinion on biological therapy. Volume 13:Number 7(2013:Jul.)
• Page Start: 1013
• Page End: 1027
• Publication Date: 2013-09
• Subjects: Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1517/14712598.2013.779250
• Languages: English
• ISSNs: 1471-2598

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> Advanced-stage Hodgkin's lymphoma (HL) has become a curable disease in the majority of patients. Despite this, about 20% of these patients relapsed or are primary refractory to the first-line treatment and high-dose chemotherapy (HDC) and autologous (Auto) hematopoietic progenitor cells transplantation (HPCT) are considered a therapeutic option.</p> <p> <bold> <italic>Areas covered:</italic> </bold> The authors reviewed HDC and HPCT treatment strategies in recurrent or refractory HL patients, with the goal of providing an overview of this approach.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> Patients younger than 60 – 65 years with relapsed disease or refractory to first-line therapy should receive a second-line chemotherapy, followed by HDC and Auto-HPCT. Progression-free and overall survival results are significantly better when a second remission or a minimal disease status is achieved before Auto-HPCT, and demonstrate that this strategy is able to cure more than half of the advanced HL patients. Myeloablative allogeneic HPCT (Allo-HPCT) has been employed in advanced phases of the disease, but there have been significant concerns due to treatment-related mortality (TRM). The safety of allogeneic transplantation has improved with the use of reduced-intensity allogeneic (RIC-Allo) HPCT strategies. Despite early favorable results, mature results of RIC-Allo available in the literature are consistent in demonstrating a lack of long-term disease control.</p> </abstract>